Duality Biotherapeutics Inc
Company Profile
Business description
Duality Biotherapeutics Inc is a key player in the antibody-drug conjugate (ADC) landscape, dedicated to the development of inventive therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond. Its pipeline of 12 in-house discovered ADC candidates is a testament to its prowess in ADC innovation, comprising: (i) seven clinical-stage ADCs with potential in a broad range of indications, two next-generation bispecific ADCs, and multiple other preclinical ADCs. Its Products DB-1303/BNT323 and DB-1311/BNT324 and key product DB-1305/BNT325, have received Fast Track Designation. DB-1303 is a late clinical-stage HER2 ADC candidate with two ongoing registrational trials and one potential global registrational study.
Contact
No. 99 Jingu Road
Unit 301, Building 3, Zone B, Suzhou Industrial Park
Phase III, Biopharmaceutical Industrial Park
Jiangsu Province
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
191
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.90 | 2.50 | -0.03% |
| CAC 40 | 7,721.90 | 22.98 | 0.30% |
| DAX 40 | 23,715.48 | 118.50 | 0.50% |
| Dow JONES (US) | 45,350.50 | 270.79 | -0.59% |
| FTSE 100 | 9,210.37 | 2.16 | 0.02% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,810.67 | 102.98 | 0.47% |
| Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
| NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
| S&P 500 | 6,493.45 | 11.95 | 0.18% |
| S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |